{
    "clinical_study": {
        "@rank": "50192", 
        "acronym": "ARCHER", 
        "arm_group": [
            {
                "arm_group_label": "1: Coronary stent+optimal medical therapy", 
                "arm_group_type": "Experimental", 
                "description": "Coronary stent on top of optimal medical therapy"
            }, 
            {
                "arm_group_label": "2: Optimal medical therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Optimal medical therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to compare optimal medical therapy alone versus percutaneous\n      coronary intervention on top of medical therapy in the setting of heart transplant recipient\n      coronary artery disease in a randomized trial.The primary endpoint assessed at 1 year is the\n      composite of death, myocardial infarction, need for transitory or permanent ventricular\n      assist device implantation, myocardial revascularization, occurrence or worsening of heart\n      failure, any graft dysfunction and/or a decrease of left ventricular ejection fraction of at\n      least 25% compared to baseline. The hypothesis of the study is the superiority of the\n      interventional management over medical therapy alone in preventing the occurrence of the\n      primary endpoint of the study."
        }, 
        "brief_title": "Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart-lung Transplant Rejection", 
        "detailed_description": {
            "textblock": "The hypothesis of the study is the superiority of the interventional management over medical\n      therapy alone in preventing the occurrence of the primary endpoint of the study assessed 1\n      year after randomization.\n\n      Objectives: To demonstrate the superiority of the interventional management on top of\n      optimal medical therapy over optimal medical therapy alone in preventing the occurrence of\n      the primary endpoint of the study assessed 1 year after randomization\n\n      Design : Multicenter, prospective randomized 1 :1, open-label blinded endpoint study\n\n      Target population : Heart transplant recipients, aged \u226518 years, without coronary artery\n      disease-related symptoms, with angiographically significant coronary artery stenoses (\u226550%\n      anatomically adequate for a revascularization by coronary angioplasty with stent\n      implantation, with no contraindication to dual antiplatelet therapy associating aspirin and\n      a P2Y12 inhibitorfor a duration of 12 monthsand with ni grade IA ACC/AHA indication for\n      revascularization\n\n      Inclusion period: 12 months (may be extended based on the inclusion rythme)\n\n      Maximum duration of participation for patients : 13 months\n\n      Total duration of the study : 37 months\n\n      Primary endpoint : The composit of death, myocardial infarction, retransplantation,\n      implantation of transitory or definitve ventricular assist devices, new or worsening heart\n      failure, graft failure and/or a decrease of left ventricular ejection fraction of at least\n      25% compared to baseline.The occurrence of any event qualifying for the primary endpoint\n      will be assessed by a Cox survival analysis stratified on center.The primary endpoint will\n      be assessed 12 months after randomization.\n\n      Secondary endpoints : Any of the individual events defining the primary outcome at 1 year\n\n      Number of patients to be included and power calculation : 80 patients per group. A 1 year\n      primary endpoint rate of 30% in the active and 50% in with an inclusion period of 24 months\n      and alpha=5% warants a 90% power using a cox model."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients \u2265 18 years old\n\n          -  Heart transplant recipient\n\n          -  Stable clinical situation\n\n          -  One or several non-critical coronary stenoses (\u2265 50% et \u2264 75% visually or\n             QCA-assessed diameter stenosis) considered as adequate for coronary stenting by the\n             operator\n\n          -  Left ventricular ejection fraction  \u2265 40%\n\n          -  Informed consentement signed by the patient\n\n        Exclusion Criteria:\n\n          -  Acute coronary syndrome\n\n          -  In-stent restenosis\n\n          -  Proof of an extensive myocardial ischemia (\u2265 7/17 segments ASE model)\n\n          -  Coronary stenosis considered as critical by the operators with slow flow\n\n          -  ACC/AHA Class IA indication for revascularization  :\n\n               -  vessel disease with left ventricular dysfunction\n\n               -  Left main stenosis\n\n               -  Severe proximal LAD stenosis\n\n          -  Contra-indication to dual antiplatelet therapy\n\n          -  Decompensated heart failure at the time of randomization\n\n          -  Pregnant or breast-feeding women- Patients participating to another clinical research\n             within 30 days before randomization- life expectancy < 1 y\n\n          -  Patients unable to observe strict medical therapy and follow-up within 1 year after\n             randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795729", 
            "org_study_id": "P081262", 
            "secondary_id": "2010-A01516-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "1: Coronary stent+optimal medical therapy", 
                "description": "Coronary revascularization", 
                "intervention_name": "Stent", 
                "intervention_type": "Device", 
                "other_name": "Any type of approved bare metal or drug-eluting coronary stent"
            }, 
            {
                "arm_group_label": [
                    "1: Coronary stent+optimal medical therapy", 
                    "2: Optimal medical therapy"
                ], 
                "description": "Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated", 
                "intervention_name": "optimal medical therapy", 
                "intervention_type": "Drug", 
                "other_name": "Any treatment required at the physicians discretion for the treatment of the patient"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart transplant", 
            "Coronary artery disease", 
            "Allograft vascular disease", 
            "Coronary stent", 
            "Optimal medical therapy", 
            "Prognosis"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "Beygui-f@chu-caen.fr", 
                "last_name": "Farzin BEYGUI, MD, PhD", 
                "phone": "33 6 78 88 41 79"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75013"
                }, 
                "name": "Piti\u00e9 Salpetriere university Hospital - Cardiology"
            }, 
            "investigator": {
                "last_name": "Farzin BEYGUI, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction: THE ARCHER TRIAL", 
        "overall_contact": {
            "email": "Beygui-f@chu-caen.fr", 
            "last_name": "Farzin BEYGUI, MD, PhD", 
            "phone": "33 6 78 88 41 79"
        }, 
        "overall_official": [
            {
                "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
                "last_name": "Farzin BEYGUI, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
                "last_name": "Pascal LEPRINCE, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
                "last_name": "Saida VARNOUS, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The composit of death, myocardial infarction, retransplantation, implantation of transitory or definitive ventricular assist devices, new or worsening heart failure, graft failure and/or a decrease of left ventricular ejection fraction of at least 25% at 1 year", 
            "measure": "The composit of death, myocardial infarction, retransplantation, implantation of transitory or definitive ventricular assist devices, new or worsening heart failure, graft failure and/or a decrease of left ventricular ejection fraction of at least 25%", 
            "safety_issue": "No", 
            "time_frame": "at 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795729"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Death at 1 year", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }, 
            {
                "measure": "myocardial infarction at 1 year", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }, 
            {
                "measure": "Retransplantation at 1 year", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }, 
            {
                "measure": "implantation of transitory or definitive ventricular assist devices at 1 year", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }, 
            {
                "measure": "new or worsening heart failure at 1 year", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }, 
            {
                "measure": "graft failure and/or a decrease of left ventricular ejection fraction of at least 25% at 1 year compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}